New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. GOOGL
5. MU
6. USO
7. APGE
8. ABBV
9. MSFT
10. IBM

Go back to New Data Confirm Biogen’s (BIIB) Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

New MS PATHS Data at ECTRIMS 2021 Confirm Biogen’s Disease-Modifying Therapies Do Not Reduce Antibody Response to COVID-19 Vaccines in People with Multiple Sclerosis

October 13, 2021 6:02 AM EDT

MS PATHS data indicate that 100 percent of people with MS treated with natalizumab, interferons or fumarates achieved an antibody response following COVID-19 vaccination
Data from this analysis also suggest that approximately 40 percent of people with MS treated with anti-CD20 and S1P disease-modifying therapies (DMT) mount an antibody response to the COVID-19 vaccineCollaborative MS PATHS network enabled rapid collection of data in the COVID-19 environment

CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) --... More